Cargando...
Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma
Ibrutinib has previously been shown to inhibit Bruton’s tyrosine kinase (BTK) and interleukin-2–inducible T-cell kinase (ITK), which mediate B-cell and T-cell receptor signaling, respectively. BTK inhibition with ibrutinib has demonstrated impressive clinical responses in a variety of B-cell maligna...
Gardado en:
| Publicado en: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society of Hematology
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5915998/ https://ncbi.nlm.nih.gov/pubmed/29669753 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017011916 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|